Gelonghui September 30 | Fuhong Hanlin-B (02696.HK) announced that Dr. ScottShi-Kau Liu has petitioned to resign as the company's executive director, member of the Board's Strategy Committee, member of the Environmental, Social and Governance Committee, and CEO of the company due to the adjustment of his personal work focus, effective September 30, 2020. After resigning, Dr. Liu will serve as the director of the company's strategic advisory committee, focusing on the company's R&D direction, the formulation of the company's strategy, and team building and development.
Mr. Zhang Wenjie has been nominated as the executive director of the second board of directors. It will not be confirmed until the company's shareholders approve it at the Extraordinary General Meeting of Shareholders, and has been appointed as the company's CEO since September 30, 2020. As the company's CEO and president, Mr. Zhang will lead the senior management team in the day-to-day management of the company and oversee the operations of the company and its subsidiaries.
Mr. Zhang, aged 52, served as the company's senior vice president, chief commercial operation officer and chief strategy officer from March 2019 to February 2020, and as the company's president, president of Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, and president of Shanghai Fuhong Hanlin Biomedical Co., Ltd., responsible for group operation and management, focusing on building the group's innovative business model, creating an international strategic layout, and successfully promoting the smooth listing of the group's core product HLX02 injectable trastuzumab (trade name in China: Han Quyou).
Mr. Zhang has over 25 years of experience in commercial operations and management in the pharmaceutical industry. Prior to joining the company, Mr. Zhang served as the general manager of Amgen China, Vice President of Oncology Business Division II of Shanghai Roche Pharmaceutical Co., Ltd., and the head of the specialty medicine and oncology department of Bayer Schilling in China. Mr. Zhang received his bachelor's degree in microbiology from Shandong University in China in July 1990 and his master's degree in business administration from Yale University in the US in May 1998.